Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.13%
0%
-18.13%
6 Months
35.27%
0%
35.27%
1 Year
92.31%
0%
92.31%
2 Years
-16.67%
0%
-16.67%
3 Years
-76.66%
0%
-76.66%
4 Years
-91.57%
0%
-91.57%
5 Years
-94.29%
0%
-94.29%
Aptorum Group Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-14.40%
EBIT Growth (5y)
12.36%
EBIT to Interest (avg)
-11.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.74%
ROCE (avg)
0
ROE (avg)
2.51%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.36
EV to EBIT
-2.68
EV to EBITDA
-2.88
EV to Capital Employed
0.43
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-16.03%
ROE (Latest)
-14.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Dec 2024
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 1 Schemes (1.39%)
Foreign Institutions
Held by 3 Foreign Institutions (0.48%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.40
1.30
-69.23%
Operating Profit (PBDIT) excl Other Income
-9.40
-16.30
42.33%
Interest
0.10
0.00
Exceptional Items
-0.20
0.00
Consolidate Net Profit
-4.30
-11.50
62.61%
Operating Profit Margin (Excl OI)
-24,394.70%
-13,511.30%
-1,088.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -69.23% vs -13.33% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 62.61% vs 57.56% in Dec 2022
About Aptorum Group Ltd. 
Aptorum Group Ltd.
Pharmaceuticals & Biotechnology
Aptorum Group Limited is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases, particularly infectious diseases and cancers (including orphan oncology indications). Through the establishment of drug discovery platforms, it enables the discovery of new therapeutics assets through systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to this, the Company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.
Company Coordinates 
Company Details
17 Hanover Square , LONDON None : W1S 1BN
Registrar Details






